AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo

Loading news article.

AbbVie Announces Topline Results From Its Phase 3 LUNA Study Of Atogepant For Preventive Treatment Of Menstrual Migraine In Adults; Atogepant Demonstrated Statistically Significant Reductions In Migraine Days Associated With Menstrual Period, Meeting Primary And All Eight Ranked Secondary Endpoints Versus Placebo | WAPE

Article summary

Related companies

Comments —